The Life Science Rundown

→ WHAT IT COVERS Cary Smithson of Leap Ahead Solutions outlines how life science companies must establish structured data governance frameworks to meet regulatory submission standards like IDMP, PQCMC, and HL7 FHIR, while building the data foundation required for safe, compliant AI adoption across R&D, regulatory, and quality functions. → KEY INSIGHTS - **Scope-First Governance:** Avoid attempting to govern all data simultaneously.

→ WHAT IT COVERS Nelly Viseux, VP of Cell Therapy Development at Puageneron, outlines how biotech leaders build resilient organizations in cell and gene therapy by embedding adaptability, empowerment, and intentional innovation into team structures, talent strategy, quality systems, and data-driven decision-making across the full development lifecycle.

→ WHAT IT COVERS Jackie Klecker, EVP and Head of Quality at Lifecore Biomedical, a 60-year-old fully integrated CDMO with 20 commercial SKUs, outlines how sponsors and CDMOs can build phase-appropriate quality systems from preclinical through commercial launch, avoiding costly delays through structured documentation, risk tools, and aligned communication.

→ WHAT IT COVERS Mike Martin, President & CEO of ISPE, outlines how Pharma 4.0 — driven by advanced robotics, AI, and integrated automation — is reshaping workforce requirements across pharmaceutical manufacturing, and what organizations, educators, and professionals must do now to build the talent pipeline pharma needs. → KEY INSIGHTS - **Preskilling over reskilling:** Rather than waiting for automation to displace workers and then reacting, pharma companies should proactively influence...

→ WHAT IT COVERS Chris Masterson, SVP and Chief Quality Officer at Tomar with 36 years in biopharma, outlines how organizations build and sustain quality-centric cultures. He covers leadership accountability, realistic three-to-five year timelines, ROI justification, measurement frameworks including the ANSI PDA Standard 06-2025, and learning from regulatory failures.

→ WHAT IT COVERS Carlos Carrillo, a drug development veteran with nearly three decades of experience, outlines the operational, regulatory, and cultural shifts biotechs must execute when transitioning from clinical stage to commercial launch, covering partner governance, compliance infrastructure, quality unit structure, and the leadership mindset required to scale sustainably.

→ WHAT IT COVERS Maria Vassileva, Chief Science and Regulatory Officer at DIA, examines how FDA and global regulators are integrating AI into drug and device review processes. Coverage spans FDA's ELSA tool deployment, validation frameworks, international agency progress, equity concerns, and the multi-stakeholder governance structures needed to sustain public trust.

→ WHAT IT COVERS Jeff Hines, VP of Quality at Karuna Medical with 37 years of pharmaceutical industry experience including 30 years at Eli Lilly, outlines leadership strategies for navigating FDA inspections across PAI, routine, and for-cause scenarios, covering inspection infrastructure, remediation execution, employee morale, and building lasting compliance culture.

→ WHAT IT COVERS Marwan Fathallah, CEO of DIA Global with 30 years in life sciences, outlines the leadership framework required to move products from concept to commercialization, covering cross-functional team structure, daily management cadence, KPI design, conflict resolution, and the cultural balance between innovation and regulatory rigor. → KEY INSIGHTS - **Cross-Functional Integration:** Embed regulatory, marketing, clinical, and R&D stakeholders into the product development process from...

→ WHAT IT COVERS Pharmacist and maternal health expert Regina Atim examines FDA's July 2025 E21 draft guidance, which establishes a framework for proactively including pregnant and breastfeeding women in clinical trials, addressing decades of exclusion rooted in the thalidomide and DES disasters of the mid-twentieth century. → KEY INSIGHTS - **Historical exclusion drivers:** Two catastrophic drug events — thalidomide (1957–1961), prescribed for morning sickness and causing birth defects, and...